TITLE

No cure for psoriasis, but treatments can help

AUTHOR(S)
Pinette, Dr. Gilles
PUB. DATE
April 2004
SOURCE
Saskatchewan Sage;Apr2004, Vol. 8 Issue 7, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Psoriasis is a common condition that causes red or purple scaly patches on your skin. Psoriasis is pronounced "sore-eye-a-sis." These patches may be thick with a rough surface, and may be on the knees, elbows and scalp or they may be widespread across the entire body. The exact cause of psoriasis remains unknown. However, people with psoriasis may get worsening of their rash with triggers such as injury to the skin, certain medications, stress, or infections in the body. Most medical treatments for psoriasis are in the form of creams and ointments that are applied to the affected area. The type of treatment is matched to the person and how bad their psoriasis is.
ACCESSION #
12967715

 

Related Articles

  • quick tip.  // Prevention;May2004, Vol. 56 Issue 5, p48 

    Reports that there is a new inject-it-yourself drug that could relieve psoriasis for the three in four sufferers dissatisfied with current treatments because of scary side effects or extra doctor visits.

  • Explosion of new dermatologic therapies offers variety of tx options. Schwanke, Jane // Dermatology Times;May2006, Vol. 27 Issue 5, p68 

    The article focuses on the biologic therapies for psoriasis and other skin diseases. The use of Raptiva has proven effective for psoriasis treatment but currently is used in treating granuloma annulare, lichen planus, alopecia areata and atopic dermatitis. The Rituxan, an anti-CD20 monoclonal...

  • Efalizumab and etanercept cost-effective choices in psoriasis.  // PharmacoEconomics & Outcomes News;6/4/2005, Issue 479, p11 

    Discusses research being done on biologics for the treatment of psoriasis. Reference to a study by K. Ramos et al, published in April 2005 of the "Journal of Managed Care Pharmacy"; Analysis of the effectiveness of efalizumab and etanercept in treating the disease; Comparison between the...

  • DERMATOLOGICAL DISORDERS.  // Monthly Prescribing Reference;Feb2011, Vol. 27 Issue 2, p122 

    A part of the book "Monthly Prescribing Reference" for February 2011 is presented. It offers an overview of pharmacological treatments for dermatological disorders including acne, psoriasis and skin infections. The drugs include Aczone from Allergan, Neoral from Novartis and Abreva from...

  • Soriatane (Acitretin) Effective in Treating Plaque-Type Psoriasis.  // Dermatology Nursing;Aug2006, Vol. 18 Issue 4, p383 

    The article reports that an oral systemic drug Soriatane (acitretin) manufactured by Connectics Corp. had a long-term efficacy on moderate-to-severe plaque-type psoriasis if taken at lower dosage. The Phase IV clinical study involving 77 adults with psoriasis reveals that taking 25 milligram of...

  • Are Tacrolimus and Pimecrolimus Effective for Psoriasis? Slawson, David // American Family Physician;3/1/2005, Vol. 71 Issue 5, p968 

    Discusses research being done on the effectiveness of tacrolimus ointment in treating facial and intertriginous psoriasis. Reference to a study by M. Lebwohl et al published in a November 2004 issue of the "Journal of the American Academy of Dermatology"; Dosage of tacrolimus applied on the...

  • Ro 20-1724: An Agent that Significantly Improves Psoriatic Lesions in Double-Blind Clinical Trials. Stawiski, Marek A.; Rusin, Louis J.; Burns, Trudy L.; Weinstein, Gerald D.; Voorhees, John J. // Journal of Investigative Dermatology;Oct79, Vol. 73 Issue 4, p261 

    Two double-blind studies comparing the effectiveness of the cyclic nucleotide-attering agent (4-[3-butoxy-4- methoxybenzyl]-2-imidazolidinone) (Ro 20-1724) vs vehicle have demonstrated that this compound can improve psoriatic lesions. Although Ro 20-1724 was not as effective as intensive...

  • Enalapril.  // Reactions Weekly;3/13/2004, Issue 992, p8 

    Discusses research being done on the side effects of enalapril in an elderly patient with psoriasis. Reference to a study by P. G. Kostakis published in a 2004 issue of the "Dermatology"; Medical history of the patient; Diagnosis of pemphigus foliaceus with psoriasis; Use of a topical...

  • NEW INDICATIONS.  // Drug Topics;6/7/2004, Vol. 148 Issue 11, p97 

    Several news reports on new indications for drugs, gathered as of June 7, 2004, are presented. Twenty-two new pathogens have been added to the labeling of Vigamox, a fourth-generation fluoroquinolone eyedrop, from the Alcon Inc. In addition to treating psoriasis arthritis, Enbrel is now approved...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics